Catherine A Ellis

US Patent:

6348585, Feb 19, 2002

Filed:

Jan 3, 2000

Appl. No.:

09/477071

Inventors:

Jeffrey Culp - Collegeville PA
Catherine E Ellis - Glassboro NJ
Dean E McNulty - Philadelphia PA

Assignee:

SmithKline Beecham Corporation - Philadelphia PA

International Classification:

C07H 2100

US Classification:

536 2351, 536 231, 536 235, 536 234, 536 243, 536 2431

Abstract:

Human Urotensin II polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing Human Urotensin II polypeptides and polynucleotides in therapy, and diagnostic assays for such.

US Patent:

6362326, Mar 26, 2002

Filed:

Dec 22, 1998

Appl. No.:

09/218467

Inventors:

Ganesh Sathe - King of Prussia PA
Catherine E. Ellis - Glassboro NJ
Wendy Halsey - Kenneth Square PA
Derk Bergsma - Berwyn PA

Assignee:

SmithKline Beecham Corporation - Philadelphia PA

International Classification:

C07H 2104

US Classification:

536 235, 536 231, 4353201, 435325, 435455, 514 44

Abstract:

The present invention relates to 11cby, in particular 11cby polypeptides and 11cby polynucleotides, recombinant materials and methods for their production. In another aspect, the invention relates to methods for using such polypeptides and polynucleotides, including the treatment of bacterial, fungal, protozoan and viral infections, particularly infection caused by HIV-1 or HIV-2; pain; cancers; diabetes; obesity; feeding and drinking abnormalities, such as anorexia and bulimia; asthma; Parkinsons disease; both acute and congestive heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ulcers; allergies; benign prostatic hypertrophy and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia or severe mental retardation, and dyskinesias, such as Huntingtons disease or Gilles dela Touretts syndrome, hereinafter referred to as âthe Diseasesâ, among others. In a still further aspect, the invention relates to diagnostic and prognostic assays for detecting diseases associated with inappropriate 11cby activity or levels. A method of performing genetic association studies for searching a disease susceptibility and/or drug response genes comprising using polymorphic markers in 11cby polynucleotides.

US Patent:

59768347, Nov 2, 1999

Filed:

Jan 9, 1997

Appl. No.:

8/775428

Inventors:

Ganesh Madhusudan Sathe - King of Prussia PA
Wendy S. Fuetterer - Kennett Square PA
Derk John Bergsma - Berwyn PA
Catherine Ellis - Glassboro NJ

Assignee:

SmithKline Beecham Corporation - Philadelphia PA

International Classification:

C12N 1512
C07K 14705

US Classification:

435 691

Abstract:

HNFJD15 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing HNFJD15 polypeptides and polynucleotides in the design of protocols for the treatment of infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ulcers; asthma; allergies; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles dela Tourett's syndrome, among others and diagnostic assays for such conditions.

US Patent:

58245049, Oct 20, 1998

Filed:

Oct 31, 1996

Appl. No.:

8/742011

Inventors:

Nabil A. Elshourbagy - King of Prussia PA
Derk J. Bergsma - King of Prussia PA
Catherine E. Ellis - King of Prussia PA

International Classification:

C12N 1512
C12N 1585
C12N 1563
C07K 14705

US Classification:

435 691

Abstract:

Human HBMBU14 polypeptides and DNA (RNA) encoding such HBMBU14 and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such HBMBU14 for the treatment of infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 and HIV-2, pain, cancers, anorexia, bulimia, asthma, Parkinson's disease, acute heart failure, atherosclerosis, hypotension, hypertension, urinary retention, osteoporosis, angina pectoris, myocardial infarction, ulcers, asthma, allergies, benign prostatic hypertrophy and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia or severe mental retardation, and dyskinesias, such as Huntington's disease or Gilles dela Tourette's syndrome, among others, are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to mutations in the nucleic acid sequences and altered concentrations of the polypeptides. Also disclosed are diagnostic assays for detecting mutations in the polynucleotides encoding the HBMBU14 and for detecting altered levels of the polypeptide in a host.

US Patent:

60751371, Jun 13, 2000

Filed:

Feb 20, 1998

Appl. No.:

9/027381

Inventors:

Jeffrey Culp - Collegeville PA
Catherine E Ellis - Glassboro NJ
Dean E McNulty - Philadephia PA

Assignee:

SmithKline Beecham Corporation - Philadelphia PA

International Classification:

C07H 2100
C12N 1516

US Classification:

536 2351

Abstract:

Human Urotensin II polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing Human Urotensin II polypeptides and polynucleotides in therapy, and diagnostic assays for such.

US Patent:

20230131598, Apr 27, 2023

Filed:

Apr 12, 2021

Appl. No.:

17/911816

Inventors:

- Brentford, Middlesex, GB
Catherine E. ELLIS - Collegeville PA, US
Steven HIRSCHFELD - Collegeville PA, US

International Classification:

C07K 16/28
A61P 35/00

Abstract:

The invention relates to a method of treating cancer, such as head and neck cancer (e.g. head and neck squamous cell carcinoma and oropharyngeal cancer), lung cancer (e.g. non small cell lung cancer), urothelial cancer, melanoma or cervical cancer, involving the combination of an ICOS binding protein (e.g. an anti-ICOS antibody) and a TIM-3 binding protein (e.g. an anti-TIM-3 antibody) and, optionally, a PD-1 binding protein (e.g. an anti-PD-1 antibody).

US Patent:

20210395367, Dec 23, 2021

Filed:

Oct 21, 2019

Appl. No.:

17/287144

Inventors:

- Middlesex, GB
Patrick MAYES - Collegeville PA, US
Catherine E. ELLIS - Collegeville PA, US
Jessica KATZ - Collegville PA, US

International Classification:

C07K 16/28
A61P 35/00

Abstract:

The present invention relates to a method of treating cancer comprising administering to the human an ICOS binding protein or antigen binding portion thereof at a dose of about 0.08 mg to about 240 mg.

US Patent:

20210324081, Oct 21, 2021

Filed:

Oct 21, 2019

Appl. No.:

17/287358

Inventors:

- Middlesex, GB
- Luzern, CH
Catherine E. ELLIS - Collegeville PA, US
Jessica KATZ - Collegville PA, US

International Classification:

C07K 16/28
A61K 9/00
A61P 35/00
A61K 39/395

Abstract:

The present invention relates to a method of treating cancer comprising administering to the human an ICOS binding protein or antigen binding portion thereof at a dose of about 0.08 mg to about 240 mg and administering to the human a PD1 antagonist.